Oligonucleotide therapy of allergic asthma

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 2 I, 1999, Pages 260-266

  Metzger, W James ^a   Nyce, Jonathan W ^b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b EpiGenesis Pharmaceuticals   (United States)

Author keywords

Antisense; Asthma; CpG DNA; DNA vaccination; Oligonucleotide therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA VACCINE;

AIRWAY OBSTRUCTION; ALLERGIC ASTHMA; B LYMPHOCYTE ACTIVATION; DRUG COST; GENE THERAPY; GENETIC POLYMORPHISM; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSURVEILLANCE; LUPUS ERYTHEMATOSUS; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RABBIT; REVIEW; VACCINATION;

EID: 0032860883     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70361-1     Document Type: Article

References (58)

1. Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999;82:233-48.
2. Frew A. Effects of anti-IgE in asthmatic subjects. Thorax 1998;53(2 Suppl):552-7.
3. Drazen JM. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997;17(Suppl):22-30S.
4. Metzger WJ. Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors. Springer Semin Immunopathol 1995;16:467-78.
5. Fahy J, Fleming H, Wong H, Liu J, Su J, Reimann J, et al. The effect of an anti-IgE monoclonal antibody on the early and late phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.
6. Boulet L, Chapman K, Cote J, Kalra S, Bhagar R, Swystum V, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:1835-40.
7. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stolz RR, et al. Use of an anti-IgE humanized monoclonal antibody in rag-weed-induced allergic rhinitis. J Allergy Clin Immunol 1997;100:110-21.
8. Nyce J. Insight into adenosine receptor function using antisense gene-knockout approaches. Trends Pharmacol Sci 1999;37:67-81.
9. Nakamura Y, Ghaffar O, Olirenstein R, Taha RA, Soussi-Gounni A, Zhang D, et al. Gene expression of the GATA-3 transcription factor is increased in atopic asthma. J Allergy Clin Immunol 1999;103:215-22.
10. Jain KK. Textbook of gene therapy. Kirkland (WA): Hogrefe & Huber; 1998.
11. Nyce JW, Metzger WJ. DNA antisense therapy in an animal model. Nature 1997;385:721-5.
12. Metzger WJ, Nyce JA. DNA antisense therapy for asthma. In: Marone G, Austin KF, Holgate ST, Kay BA, Lichenstein LM, editors. Asthma and allergic diseases, physiology, immunopharmacology and treatment: 5th international symposium. London: Academic Press; 1998. p. 375-87.
13. Galant SP. Therapeutic targets in bronchial asthma pathophysiology. Pediatr Asthma Allergy Immunol 1998;12:241-51.
14. Turner MO, Noertjojo K, Vedal S, Bai T, Crump S, Fitzgerald JM. Risk factors for near-fatal asthma: a case control study in hospitalized patients with asthma. Am J Respir Crit Care Med 1998;157:1804-9.
15. 2-agonists. In: Page CP, Metzger WJ, editors. Drugs and the lung. New York: Raven Press; 1994 p 1-45.
16. O'Connor BJ, Crowther SD, Costello JF, Morley J. Selective airway responsiveness in asthma. TIPS 1999;20:9-11.
17. Rosenstreich D, Eggleston P, Kattan M, Baker D, Slavin R, Gergen P, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med 1999;36:1356-63.
18. Gennuso J, Epstein LH, Paluch RA, Cerny F. The relationship between asthma and obesity in urban minority children and adolescents. Arch Pediatr Adolesc Med 1998;152:1197-200.
19. Vogel G. New clues to asthma therapies. Science 1997;276:1643-6.
20. Bosquet J, Chanez P, Lacoste JY, White R, Vic P, Godard P, et al. Asthma: a disease of remodeling of airways. Allergy 1992;47:3-11.
21. Cockcroft D, Swystun S. Asthma control verses asthma severity. J Allergy Clin Immunol 1996;98:1016-8.
22. Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: is there a solution to the problem. Ann Allergy Asthma Immunol 1997;79:177-85.
23. Metzger WJ, Moseley P, Nugent K, Richerson HB, Hunninghake GW. Local antigen challenge and bronchoalveolar lavage of allergic asthmatic lungs. Chest 1985;87:155-6S.
24. Adelroth E. How to measure airway inflammation: bronchoalveolar lavage and airway biopsies. Can Resp J 1998;5(A Suppl):18-21A.
25. Bradley BL, Azzawi M, Jacobson M, Assoufi B, Collins JV, Irani AM, et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991;88:661-74.
26. Romagnani S. The Th2 hypothesis in allergy - "eppur si muove!" [research trends]. ACI Int 1998;10:158-64.
27. Brewster CE, Howarth PH, Djukanovic R, Wilson J, Holgate ST, Roche WR. Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1990;3:507-11.
28. Roche WR, Beasley R, Williams JH, Holgate ST. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989;1:520-4.
29. 1: a longitudinal study in the elderly. Am J Respir Crit Care Med 1995;151:656-62.
30. Chanez P, Vignola AM, Vic P, Guddo F, Bonsignore G, Godard, et al. Comparison between nasal and bronchial inflammation in asthmatic and control subjects. Am J Respir Crit Care Med 1999;159:588-95.
31. Ali S, Mustafa SJ, Metzger WJ. Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late phase airway obstruction: evidence for an inducible adenosine A1 receptor. J Pharmacol Exp Ther 1993;268:1328-34.
32. Bjorck T, Gustatsson LE, Dahlen SE. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis 1992;145:1087-91.
33. Hakonarson H, Shanbaky I, Guerra FM, Grunstein MM. Modulation of adenosine-A1, bradykinin-B1, and histamine-H1 receptor expression and function in atopic asthmatic sensitized airway smooth muscle [abstract]. Am J Respir Crit Care Med 1998;157:A662.
34. Collins MG, Hourani SM. Adenosine receptor subtypes. TIPS 1993;14:360-6.
35. Linden J. Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 1994;15:298-306.
36. Coward WR, Sagara H, Church MK. Asthma, adenosine, mast cells and theophylline. Clin Exp Allergy 1998;28(3 Suppl):42-6.
37. Polosa R, Holgate ST. Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma? Thorax 1997;52:437-8.
38. Krieg AM. The CpG motif: implications for clinical immunology. Bio-Drugs 1998:341-6.
39. Huang S. Molecular modulation of allergic responses. J Allergy Clin Immunol 1998;102:887-92.
40. Kline JN, Waldschmidt TJ, Businga TR, Lemish JE, Weinstock JV, et al. Cutting edge: modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998;160:2555-9.
41. Broide D, Schwarze J, Tighe H, Gifford T, Nguyen M, Malek S, Thorne PS, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998;161:7054-62.
42. Sur S,Wild JS, Choudhury BK, Sur N, Alam R, Klinman DM. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999;162:6284-93.
43. Spiegleberg HL, Tighe H, Roman M, Broide D, Raz E. Inhibition of IgE formation and allergic inflammation by allergen gene immunization and by CpG motif immunostimulatory oligodeoxynucleotides. Allergy 1998;53:93-7.
44. Matveeva O, Felden B, Tsodikov A, Johnston J, Monia BP, Atkins JF, et al. Prediction of antisense oligonucleotide efficacy by in vitro methods. Nat Biotech 1998;16:1374-5.
45. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. J Allergy Clin Immunol 1998;102:558-62.
46. Zeiler T, Taivainen A, Rytkonen M, Rautiainen J, Karjalainen H, Mantyjarvi R, et al. Recombinant allergen fragments as candidate preparations for allergen immunotherapy. J Allergy Clin Immunol 1997;100(6):721-27.
47. Schramm G, Kahlert H, Suck R, Weber B, Stuwe H, Muller WD, et al. "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J Immunol 1999;162:2406-14.
48. McCluskie MJ, Davis HL. Cutting edge: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998;161:4463-6.
49. Kovarik J, Bozzotti P, Love-Homan L, Pihlgren M, Davis HL, Lambert P, et al. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol 1999;162:1611-7.
50. Yi A, Krieg AM. Cutting edge: rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol 1998;161:4493-7.
51. Ichino M, Mor G, Conover J, Weiss WR, Takeno M, Ishii KJ, et al. Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine. J Immunol 1999;162:3814-8.
52. Kim JJ, Nottingham LK, Wilson DM, Bagarazzi ML, Tsai A, Morrizon LD, et al. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. Vaccine 1998;16:1828-35.
53. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1(Th1) immunity. J Exp Med 1997;186:1623-31.
54. Stepkowski SM. Application of antisense oligodeoxynucleotides for organ transplantation. Transplantation Proc 1998;30:2142-5.
55. Krieg AM, Steinberg AD. Potential of antisense technology in the treatment of immunological disorders. Clin Immunother 1995;4:169-79.
56. Ali S, Leonard SA, Kukoly C, Nyce J, Metzger WJ. Pharmacokinetics of a respirable antisense oligonucleotide (EPI2010) following aerosol delivery in rabbits [abstract]. Am J Respir Crit Care Med 1999;159:A626.
57. Field AK. Viral targets for antisense oligonucleotides: a mini review. Antiviral Res 1998;37:67-81.
58. Kim H, Kim K, Lee E. Specific inhibition of immunoglobulin E-mediated allergic reaction using antisense FcεRIα oligodeoxynucleotides. Immunology 1998;93:589-94.